

Priorités pour 2018 - 2020







Better health and care, economic growth and sustainable health systems

- Personalised medicine
- Innovative health & care industry
- Global health
- Sustainable and evidence based health and care systems



Decoding the role of the overall environment for health and well-being

Human exposome – global changes and health

Digital transformation in Health and Care

e-Health and m-Health

ICT for Active and Healthy

Ageing



Trusted Big Data solutions and Cybersecurity for Health and Care







Structure du programme de travail 2018 - 2020

Call 1. Better Health and care, economic growth and sustainable health systems,

(21 calls, 11 CSA)

1.1 Personalised medicine

1.2 Innovative health and care industry

1.3 Infectious diseases and improving global health

1.4. Innovative health and care systems - Integration of care

1.5 Decoding the role of the environment for health and well-being







Call 2. – Digital transformation in Health and Care (8 calls, 5 CSA)

Budget 2018-2019 197,5 M€



Call 3. – Trusted digital solutions and Cybersecurity in Health and Care (2 calls, 1 CSA)



Budget 2018-2019 96M€



Nouveautés pour le WP 2018 - 2020

- Programme de travail en 3 ans Seulement les titres des appels 2020 sont connus, toujours en discussion et seront publié courant 2018
- ➤ Call 2018 en 1 étape seulement (clôture le 10 avril 2017)
 Sauf pour le BHC-15-2018 (2 étapes)
- Appels larges basés sur des défis de société
- ➤ Ligne pilote « *lump sum* » : BHC-15-2018

La CE teste une nouveau mode de financement par somme forfaitaire

- Budget complet détaillé par work package et par bénéficiaire lors de la proposal
- Expert financier dans le comité d'évaluation
- Budget du projet négocié et signé dans le grant agreement avant le début du projet
 → plus de justification financière
- Attention, tous les détails et conditions ne sont pas encore connus à ce jour





Comment lire une ligne d'appel?

1.4. Innovative health and care systems - Integration of care

SC1-BHC-23-2018 (ex-13): Novel patient-centred approaches for survivorship, palliation and end-of-life care

Specific challenge

Health conditions linked to end-of-life issues, life-threatening non-communicable diseases, late or long term side effects and consequences of diseases and their treatments impact quality of life and pose an immense societal and economic burden. [...] Therefore a need exists to strengthen the evidence base for available effective interventions improving quality of life in the domains of palliative, end-of-life and survivorship care.

Scope

Proposals should demonstrate, based on preliminary results, the effectiveness of new, improved or specifically adapted interventions to relieve symptoms and suffering caused by life-threatening non-communicable diseases, serious late and long-term side effects of disease treatments in patients and survivors, or symptoms that occur at the end of life. Randomised clinical trials or observational studies of new or improved patient-centred interventions, targeting children and/or adults, should be considered for this topic.

The Commission considers that proposals requesting a contribution from the EU of between EUR 3 and 4 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected impact

- Reduced suffering or improved well-being of patients in need for palliative, end-of-life or survivorship care.
- Improved quality, effectiveness and cost-effectiveness of palliative, end-of-life or survivorship care services as well as access to care.

Type of action: RIA

Thème

Titre et date du call

Défi spécifique à relever justification

Périmètre de l'action à adresser

Indication Budget

Impact attendu en lien avec le défi

Type de projet



Call 1. Better Health and care, economic growth and sustainable health systems

| 1.1 Perso | onalised M | Budg. Projet | Budget Total | Туре | |
|-------------|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|------|-----|
| BHC-03 | 2018 | Exploiting research outcomes and application potential of the human microbiome for personalised prediction and prevention of disease | 13-14 | 50 | RIA |
| 10 a | vril 18 | Develop personalised approaches and clinical tools to predict and prevent diseases by integration of high quality microbiome and other -omics data produced by large scale initiatives - Production of new data to deliver more valuable tools - Related topics in SC2 and IMI | | | |
| BHC-05 | 2018 | International flagship collaboration with Canada for human data storage, integration and sharing for developing personalised medicine approaches | 6 | 40 | RIA |
| 10 avril 18 | | Improving international collaboration in data repositories, developing models and methods for data deposition, curation and exchange procedures (interoperability). - Multidisciplinary approach is key aspect - Several independent projects funded but "could" be coordinated by an existing consortium | | | |
| BHC-01 | 2019 | Understanding causative mechanisms in co- and multimorbities | 4-6 | 70 | RIA |
| | Oct. 18 Apr. 19 | Identify causative mechanisms combining mental and physical disorders via the integration of Basic, pre-clinical and/or clinical research (clinical trials excluded) - Biomarkers development for diagnostic and monitoring - Continuation of PHC-3 (WP 2014-2015) | | | |
| BHC-02 | 2019 | Systems approaches for the discovery of combinatorial therapies | 4-6 | 50 | RIA |
| | Oct. 18 Apr. 19 | Build more sophisticated computational framework to predict patient responses to combinatorial therapies : pre-clinical and clinical validation - Project focus on marketed therapeutic intervention and/or products in final stage of development (phase 1 and 2 excluded) - Drug repurposing is included in the scope | | | |

Call 1. Better Health and care, economic growth and sustainable health systems (suite)

| 1.7 Innovative Health care industry | | | Budg. Projet | Budget Total | Туре |
|-------------------------------------|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|-----------------|------|
| BHC-09 | 2018 | Innovation platforms for advanced therapies of the future | 12-15 | 50 | RIA |
| 10 a | vril 18 | Creation of knowledge and exploitation platforms around innovative concepts for advanced therapies -To build possible new therapeutic approaches -Component: Basic biology and its mode of action, proof-of-concept, safety, efficacy etc - Business model to exploit results, outreach and public information activities - Advanced therapies definition: EC Regulation 1394/2007 | | | |
| BHC-07 | 2019 | Regenerative medicine: from new insights to new applications | 6-8 | 50 | RIA |
| 09 avril 19 | | Develop regenerative processes to address unmet clinical needs of large patient group -Explain how the approach is regenerative -Any step of the innovation chain -Conventional method or device alone are excluded - Show how it will be delivered to patient, potential exploitation and regulatory aspects | | | |
| BHC-10 | 2019 | Innovation Procurement : Next generation sequencing (NGS) for routine diagnosis | 9-11 | 40 | PCP |





Call 1. Better Health and care, economic growth and sustainable health systems (suite)

| 1.3 Infect | tious dise | Budg. Projet | Budget Total | Туре | |
|--------------|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|------|-----|
| BHC-15 | 2018 | New anti-infective agents for prevention and/or treatment of neglected infectious diseases (NID) | 5-10 | 45 | RIA |
| 1 | ev. 18 sep 18 | The call targets the Neglected infectious diseases Further development of vaccines and/or drugs candidates - bridge the gap between preclinical and clinical development - help advance already existing candidates along the development pipeline - Neglected viral disease excluded - Participation of disease endemic countries | | | |
| BHC-16 | 2018 | Global Alliance for Chronic Disease (GACD) 1 | - | 20 | RIA |
| 10 av | vril 18 | | | | |
| BHC-21 | 2018 | Research on HIV and/or tuberculosis and/or hepatitis C in patients with mono-, co- infections or comorbidities in the contest of the collaboration between the European Union and the Russian Federation | - | 10 | RIA |
| 10 avril 18 | | TB: To investigate biomarkers or new diagnostic tests for early screening of TB risk groups for TB infection and identification of antimicrobial drug resistance. HIV: To investigate the susceptibility to HIV and/or disease progression rate after infection, including various HIV serotypes, development of genetically-defined adverse effects (AE) during antiretroviral therapy (ART) and concomitant diseases (comorbidities and coinfections, including with tuberculosis). HCV: To evaluate the genetic determinants of the virus and the host, comorbid conditions that can be involved in disease progression and HCV treatment strategies. Address one or more subtopics Use of already established European cohort networks Comorbidities of HIV or TB infections with non-communicable diseases (NCDs) should be | | | |



considered





Call 1. Better Health and care, economic growth and sustainable health systems (suite) 1.3 Infectious diseases and improving global health (suite)

| BHC-13 | 2018 | Mining big data for early detection in infectious disease threats driven by climate change and other factors | 12-15 | 30 | RIA |
|-------------------------|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|------|-----|
| 10 avr | il 18 | Development of technology which allows the pooling, access analysis and sharing of relevant data Innovative bioinformatics and modelling methodologies (risk modelling and mapping) Ready to use Analytical tools for early warning, risk assessment and monitoring of (re)emerging infectious diseases threats - Data from a wide range of relevant sources (NGS, surveillance data, societal data) - Data privacy and Data security must be taken into account | | | |
| BHC-14 | 2019 | Stratified host-directed approaches to improve prevention and/or treatment of infectious disease | 6-10 | 95 | RIA |
| 02 Oct - 09 A | | To develop novel therapeutic or preventive approaches on the basis of specific factors identified in the host or the host-pathogen interaction Stratification of individuals based on theses characteristics and tailor the treatment or the preventive measure accordingly To test emerging concepts in drug and/or vaccine development in order to address the problem of antimicrobial drug resistance and to optimize therapeutic, curative or preventive measures against infectious diseases of major concern for Europe - Differences in factors such as age, gender and genetic variation among the human population should be taken into consideration - The proposals should focus on late pre-clinical and/or clinical research | | | |
| BHC-18 10 avr | 2019 il 18 | EU-CELAC collaboration for research on non-communicable diseases To support EU-CELAC research networks addressing common healthcare challenges and supporting data sharing and capacity building, in the area of non-communicable diseases | 1-3 | 22 | RIA |
| BHC-19 | 2019 | Implementation research for maternal and child health | 2-4 | 25 | RIA |
| | t. 18 pr. 19 | New or improved health service delivery interventions that strengthen maternal and child health; The scaling up and/or adapting of existing interventions to new contexts - Proposals should focus on implementation research for improving maternal and child health during the first '1000 days' from pregnancy until two years of age - Neither pre-clinical research nor clinical trials in the context of product development are within the scope of this call | | ***, | |





Call 1. Better Health and care, economic growth and sustainable health systems (suite)

| 1.4 Innovative health and care systems - Integration of care | | | | Budget Total | Туре |
|--------------------------------------------------------------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|-----------------|------|
| BHC-23 | 2018 | Novel patient centered approaches for survivorship, palliation and/or end-of-life care | 3-4 | 40 | RIA |
| 10 avr | ril 18 | Demonstrate effectiveness and cost-effectiveness of new, improved or specifically adapted pharmacological or non-pharmacological intervention to relieve symptoms and suffering caused by: - Life threatening non-communicable disease - Serious late and long term side effect of disease treatments in patients and survivor - Symptoms that occur at the end of life Randomized clinical trial/observational studies to be considered | | | |
| BHC-26 | 2018 | HTA research to support evidence-based healthcare | 8-10 | 10 | RIA |
| 10 avri | il 18 | Develop new or improved approaches and framework to address Specific types or groups of health technologies Selected therapeutic areas Use of real-world data Effort should be directed at implementation of methodological work in the 3 areas | | | |
| BHC-22 | 2019 | Mental Health in the workplace | 2-4 | 30 | RIA |
| 02 Oct - 09 A | | Develop and implement intervention(s) that employer/organization can take to promote good mental health and prevent mental illness in the workplace - Co-morbidities to be addresses - Unpaid work and work at home include in the scope | | | |
| BHC-25 | 2019 | Demonstration pilots for implementation of Personalised Medicine in health care | 15-20 | 60 | RIA |
| 02 Oct - 09 A | 1 | Demonstrate the benefit for individuals as well as the implementability and economic viability of PM approaches in real life healthcare settings Diseases with high burden to society Use of big data and HPC Engage partners (region or cities) having adopted PM approaches already | | | |





Call 1. Better Health and care, economic growth and sustainable health systems (suite)

| 1.5 Deco | ding the I | Budg. Projet | Budget Total | Туре | |
|--------------|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|------|-----|
| BHC-27 | 2018 vril 18 | New testing and screening methods to identify endocrine disrupting chemicals Increase the quality and efficiency of existing methods to meet demanding and evolving regulatory requirements worldwide research should improve and harmonise screening and testing protocols/strategies and hazard/risk assessments with better and faster tools, methods or models, including high-throughput and <i>in silico</i> methods - Focus should be on the most urgent regulatory needs (thyroid axis, female reproduction, non-genotoxic carcinogens and developmental neurotoxicity) - Potential work with JRC to be considered in the proposal | 4-6 | 50 | RIA |
| BHC-28 | 2019 | The Human Exposome Project: a toolbox for assessing and addressing the impact of environment on health | 8-12 | 50 | RIA |
| 0 9 a | vril 19 | Collect, combine and analyze large data sets offering new possibilities to understand the contribution of environmental factors to the global health burden of common chronic diseases identification of the most important environmental risk factors for the development of major NCDs across the life course (including in utero) - Well-designed retrospective epidemiological studies may be included - Creation of a prospective Europe-wide exposomics cohort and biobank, integrating behavioural, socio-economic factors and clinical records - Coordination mechanism between the projects funded will be required and will be added at the grant preparation stage | | | |





Call 2. Digital Transformation in Health and Care

| | | | Budg. Projet | Budget Total | Туре |
|-------------|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|-----------------|------|
| DTH-03 | 2018 | Adaptive smart working and living environment supporting active and healthy ageing | 3-4 | 25 | RIA |
| 17 av | ıril 18 | Proposals should develop and validate digitally enabled adaptive services and solutions leading to smart work environments for older adults Proposals should be based on trans-disciplinary research, involving behavioural, sociological, psychological, medical and other relevant disciplines, including gender and cultural aspects. Development and integration of unobtrusive, adaptive solutions for age-friendly living and working environments Proposals should build on active user engagement in order to ensure the understanding of user needs | | | |
| DTH -07 | 2018 | Exploiting the full potential of in-silico medicine research for personalised diagnostic and therapies in cloud-based environments | 10-15 | 37 | RIA |
| 17 av | ıril 18 | Develop and validate software tools and devices for diagnostic or treatment based on computational modelling and simulation applied in biology and physiology The solutions should enable decision making for the choice of drugs, devices or other biomedical products, procedures, interventions, in vitro and in vivo diagnostics methods and tools, or combined diagnostics and treatments The teams are expected to use shared infrastructures and e-infrastructures, building on existing capacity and expertise | | | |
| DTH-08 | 2018 | Prototyping a cloud-based standardised Personal Health µRecord/Electronic Health Record for Europe | 4-6 | 20 | IA |
| 17 avril 18 | | eHealth interoperability standardisation and harmonisation This research and innovation action is expected to prototype on a larger scale The proposal shall demonstrate its ability to providing a cloud-based harmonised/standardised/interoperable health record | | | |







Call 2. Digital Transformation in Health and Care (suite)

| | | | Budg. Projet | Budget Total | Туре |
|--------------|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|-----------------|------|
| DTH-01 | 2019 | Big data and Artificial Intelligence for monitoring health status and quality of life after the cancer treatment | 3-5 | 35 | RIA |
| 02 av | vril 19 | Improve quality of life after the cancer Proposals should focus and deliver on how to better acquire, manage, share, model, process and exploit big data to effectively monitor health status of individual patients determining and monitoring the combined effects of cancer treatment, environment, lifestyle and genetics on the quality of life, enabling early identification of effects that can cause development of new medical conditions and/or impair the quality of life | | | |
| DTH-05 | 2019 | Large scale implementation of digital innovation for health and care in an ageing society | 2-5 | 10 | PPI |
| 02 av | vril 19 | to specify, purchase and deploy ICT based solutions (made up of services and ICT products to enable the provision of services) for active and healthy ageing through a common supply and demand side dialogue | | | |
| DTH-09 | 2019 | Scaling up the univocal Identification of Medicinal products | 4-6 | 19 | IA |
| 02 avril 19 | | enabling and fostering the use of a common EU medicinal Product repository (ISO IDMP compliant) to fulfil the ePrescription/eDispensation in a cross-border setting use case Inclusion of a wide range of relevant stakeholders and experts including inter alia National Competent Authorities, IT Integrators, producers of ePrescribing, clinical record systems, SDOs | | | |





Call 2. Digital Transformation in Health and Care (Suite)

| | | | Budg. Projet | Budget Total | Туре |
|--------------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|-----------------|------|
| DTH-10 | 2019 | Digital health and care services | 5-6 | 22 | PCP |
| 02 av | ril 19 | Key challenges that could be addressed are patient empowerment, self-management, patient safety, patient involvement, chronic disease management, diagnosing, hospital logistics, skills and independent living Applicable ICT domains e.g., telemedicine, mHealth, IoT, shared open source IT-based platforms, etc. as will be defined in the market consultation process | | | |
| DTH-11 | 2019 | Large Scale pilots of personalised & outcome based integrated care | 4-6 | 20 | IA |
| 02 avril 19 | | foster the large-scale pilots for deployment of trusted and personalised digital solutions dealing with Integrated Care to supporting and extending healthy and independent living for older individuals who are facing permanently or temporarily reduced functionality and capabilities | | | |





Call 3. Trusted digital solutions and Cybersecurity in Health and Care

| | | | Budg. Projet | Budget Total | Туре |
|------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|-----------------|------|
| SU-TDS-01 | 201 | Toolkit for assessing and reducing cyber risks in hospitals and care centres to protect privacy/data/infrastructures | 3-5 | 35 | RIA |
| 17 avril 1 | 8 | to foster large-scale deployment of integrated digital solutions which will bring improved quality of life 1) develop and deploy innovative and user-led digital solutions capable of supporting and extending healthy and independent living for older individuals who are facing permanently or temporarily reduced functionality and capabilities 2) develop and deploy innovative and user-led solutions building on big data for personalised risk detection, advanced health monitoring and early interventions | | | |
| DT-ICT-12 | 201 | Smart and healthy living at home Focus area "Digitising and transforming European Industry, Platforms and Pilots" | 15-20 | 35 | IA |
| 23 Oct 18 | 8 | Platforms for smart living at home that integrates a mix of advance ICT. 2 areas to address: - Digital solutions for sustaining healthy and independent living | | | |

- Personalised early risk detection





Autres Appels concernant la Santé dans H2020

- > ERANET et JPI (joint programme initiatives)
- ➤ Pilier Excellence scientifique : FET Proactive et FET Flagship
- ➤ Défis sociétaux : SC5, Climat
- > Pilier Primauté Industrielle : NMBP, SME Instrument







ERA-nets en santé

Maladies rares

Cancer

Nanomédecine

Neurosciences

Maladies infectieuses Humaines Exclusion : VIH, hépatites, malaria et tuberculose

Médecine systémique

Biologie de Synthèse















INITIATIVE CONJOINTE DANS LE DOMAINE DES MALADIES **NEURODÉGÉNÉRATIVES**

→ Mettre en commun de manière plus efficace les forces de recherche sur les maladies neuro dégénératives



RÉSISTANCE ANTI-MICROBIENNE

Appel à projets transnational sur les approches novatrices pour lutter contre la résistance antibactérienne



NUTRITION





Future and Emerging Technologies (FET)

Recherche collaborative, **très risquée**, interdisciplinarité, fort potentiel technologique sur moyen/long terme: **incubateur d'idées innovantes**

Open, light and agile

Roadmap-based research

Future and Emerging Technologies

Individual research projects

Early Ideas

FET Open

Exploring novel ideas

Open research clusters

Incubation

FET Proactive

Developing topics & communities

Common research agendas

Large-Scale Initiatives

FET Flagships

Addressing grand challenges

Un programme OUVERT

Un programme thématique

Une feuille de route sur 10 ans pour un domaine d'intérêt majeur



FETPROACT-01-2018: emerging paradigms and communities

An innovation ecosystem around a new technological paradigm

- Area 1 Artificial organs, tissues, cells and sub-cellular structures (15M€) Integrative biology, bio engineering, replacement, control or repair of vital organ functions, use in the development of personalized treatment, drugs or vaccine, etc..
- Area 3 Living technologies (20M€) Understanding of essential features of living systems such as physical autonomy, growth, interaction and enaction, adaptation and evolution, among others. Hybrid materials and systems with programmable features of shape, structure, functionality and evolvability; Work on ethical implications must be included

• Budget/projet : 4 à 7M€ pour 5 ans

Budget global : 88M€

Deadline: 18 Septembre 2018







FET Flagships

2. Health and the Life Sciences

Proposals should address any of the following topics:

Disruptive ICT to Revolutionise Healthcare: New technologies and approaches aiming at a paradigm shift to prevention and treatment of diseases. This includes in particular methods to use patients' genetic make-up to provide individualised prevention and treatment, nano-medicine approaches including novel uses of bio-sensors, organ-on-a-chip technologies, radically new technologies for drug development, precision medicine, regenerative medicine and biofabrication techniques to replace human cells, tissues and whole organs.

Understanding Life by Exploring the Genome and the Cell: Novel technologies and approaches that enable a paradigm shift in studying and understanding the foundational building blocks of life, e.g., the functioning of the human cell and full genome/proteome/metabolome, opening up radically new opportunities in biology, advanced drug delivery and screening methods, and developing novel bionano-devices and technologies and advanced analytical and morphological technologies







Call - Building a low-carbon, climate resilient future: climate action in support of the Paris Agreement

Climate adaption, impacts and services

LC-CLA-03-2018: Climate impacts in Europe (RIA)

- a. Climate impact on health in Europe
- b. Global climate impacts from a European perspective

| ì | Budget | total | • | 20M€ |
|---|---------------|-------|---|--------|
| | Duugci | totai | • | ZUIVIC |

- Budget par projet : 5-7M€
- ☐ Deadline: 27 Feb 2018 (First

stage)

Scope:

Review, report and progress on the current state-of-the art knowledge on all links between climate change and impacts on human health in Europe

Identify associated costs and suggest effective adaptation strategies, quantify health cobenefits from mitigation and early adaptation, target research actions to address key issues and identified research gaps and prioritise those that are of significance for Europe.





Piler II: focus sur les Technologies de l'Information et de la Communication

| Technol | Technologies for Digitising European Industry | | | | Туре |
|------------|-----------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|---------------------|--------------------------------------------------------|
| ICT-05 | 2019 | Application driven photonics components and Photonics Manufacturing Pilot Lines (pour l'appel RIA uniquement) | 3-6M | 60 (pour 3 thèmes) | RIA |
| 2 a | ıvril 19 | IA, RIA et CSA, dont une RIA spécifique sur l'imagerie/santé: ii. Photonics systems for advanced imaging to support diagnostics driven therapy (RIA) | | | |
| ICT-09 | 2018 | Electronic Smart Systems (ESS) | A déf | 39 | RIA |
| 17 | avril 19 | Plusieurs appels (IA, RIA, CSA), dont une RIA sur: 2. Advances in bio-electronics smart systems. TRL 5 (RIA) | | | |
| ICT-13 | 2019-202 | 0 Robotics in Application Areas | 3-6(RIA) 7-9M (IA) | 20 (RIA) 53 (IA) | RIA/IA/CSA |
| 2 a | vril 19 | a) RIA: Innovative approaches to hard research problems in relation to applications of robotics in promising areas; To enable substantially improved solutions to challenging technical issues. b) IA: Establish large-scale pilots capable of demonstrating the use of robotics at scale in actual or highly realistic operating environments. c) CSA Application areas: healthcare, infrastructure inspection and maintenance, agri-food and agile production | | | |
| ICT-13 | 2019-202 | 0 Robotics Core Technology | 5-10 | 42 | CSA |
| | | 4 Core Technologies: Al and Cognition; Cognitive Mechatronics; Socially cooperative human-robot interaction; Model-based design and configuration tools. Proposals should address one of the four core technologies and meet the requirements of applications in the four prioritised application areas: healthcare, infrastructure inspection and maintenance, agri-food and agile production). | | | Liberai - Egallai - Fraterniai République Française |



| Platforms a | nd Pilots | Budg. Projet | Budget Total | Туре |
|---------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|-----------------|------|
| DT-ICT-12 | 2019 Smart and healthy living at home | 15-20 | 60 | IA |
| 23 Octo 18 | A mix of advanced ICT ranging from biophotonics to robotics, from artificial intelligence to big data and from IoT to smart wearables can address these challenges. A platform for smart living at home should integrate these technologies in an intelligent manner. The pilots should build on open platforms, standardised ontologies, APIs and results from IoT-based smart living environments, service robotics and smart wearable & portable systems and clearly go beyond current state of the art in terms of scale, the capabilities for personalisation, adaptation, and user acceptance of the proposed solutions and services. Two areas are of particular importance in this context: Intelligent and personalised digital solutions for sustaining and extending healthy and independent living Personalised early risk detection and intervention | | | |
| DT-ICT-13 | 2020 The smart hospital of the future | TRD | TRD | IΔ |

Plus d'infos: PCN ICT: ICI







| OPEN INNOVATION HUBS | | Budget Total | Туре |
|-----------------------------------------------------------------------------------------------------------|-------|-----------------|------|
| DT-NMBP-02 2018 Open Innovation Hubs for Safety Testing of Medical Technologies for Health (TRL4 to TRL7) | 7-15M | 75 | IA |

GOVERNANCE, SCIENCE-BASED RISK ASSESSMENT AND REGULATORY ASPECTS

| NMBP-13 | 2018 Risk Governance of nanotechnology (TRL 4-6) | 5 M | 72 | RIA |
|---------|---------------------------------------------------------------------------------------------|------|-----|-----|
| NMBP-14 | Nanoinformatics: from materials models to predictive toxicology and ecotoxicology (TRL 4-6) | 6M | 72 | RIA |
| NMBP-15 | 2019 Safe by design, from science to regulation: metrics and main sectors (TRL 4-6) | 5-6M | 65 | RIA |
| NMBP-16 | Safe by design, from science to regulation: behaviour of multi-component nanomaterials | TBD | TBD | RIA |
| NMBP-17 | 2020 Regulatory science for medical technology products | TBD | TBD | RIA |

MEDICAL TECHNOLOGY INNOVATIONS

| NMBP-21 | 2020 Custom-made biological scaffolds for specific tissue regeneration and repair | TBD | TBD | RIA |
|---------|-----------------------------------------------------------------------------------|-------|-----|-----|
| NMBP-22 | 2018 Osteo-articular tissues regeneration (TRL 3-5) | 4-6 M | 24 | RIA |
| NMBP-15 | 2020 Next generation organ-on-chip | TBD | TBD | RIA |









Horizon 2020 : ce qu'il faut retenir

- H2020 finance toute la chaîne de l'innovation
- Les projets de recherche collaborative rassemblent des équipes apportant chacune une expertise complémentaire
- Les projets sont financés en coût total et 100% des coûts sont financés pour les laboratoires
- Les sujets sont abordés sous un angle sociétal : relever les défis pour améliorer la vie des citoyens
- Il est conseillé de se rapprocher le plus vite possible des structures d'aide au montage







Sophie Decamps, PhD, Chargée de Mission Pôle Relations Européennes, Coordinatrice du Point de Contact National H2020, <u>sophie.decamps@inserm.fr</u>

Virginie Sivan, PhD, Affaires européennes, CEA, Direction de la Recherche Fondamentale Membre du Point de Contact National santé <u>Virginie.sivan@cea.fr</u>



